Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 33278935

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2020 Dec 5
First author
Cortes J

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2021 Jul 3;398(10294):24. doi: 10.1016/S0140-6736(21)00380-9.
    note
    Source null
    related pmid
    34217392
    relationship
    Comment in

Authors and identifiers

  1. name
    Cortes J
    type
    Author
  2. name
    Cescon DW
    type
    Author
  3. name
    Rugo HS
    type
    Author
  4. name
    Nowecki Z
    type
    Author
  5. name
    Im SA
    type
    Author
  6. name
    Yusof MM
    type
    Author
  7. name
    Gallardo C
    type
    Author
  8. name
    Lipatov O
    type
    Author
  9. name
    Barrios CH
    type
    Author
  10. name
    Holgado E
    type
    Author
  11. name
    Iwata H
    type
    Author
  12. name
    Masuda N
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Cortes J
    type
    Author
  2. name
    Cescon DW
    type
    Author
  3. name
    Rugo HS
    type
    Author
  4. name
    Nowecki Z
    type
    Author
  5. name
    Im SA
    type
    Author
  6. name
    Yusof MM
    type
    Author
  7. name
    Gallardo C
    type
    Author
  8. name
    Lipatov O
    type
    Author
  9. name
    Barrios CH
    type
    Author
  10. name
    Holgado E
    type
    Author
  11. name
    Iwata H
    type
    Author
  12. name
    Masuda N
    type
    Author
bibliography ids
  1. nci-bib-a6c6619216a1865c6ec40fbc
book metadata
content sha256
8e44f7f85903d3bf929b4ef0b02734d49b192f89c4f85f3d8fc39bc3934feed2
document type
citation
dois
  1. 10.1016/S0140-6736(20)32531-9
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:33278935
immutable id
pubmed:33278935@8e44f7f85903d3bf929b4ef0b02734d49b192f89c4f85f3d8fc39bc3934feed2
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
10265
name
Lancet (London, England)
nlm unique id
2985213R
pages
1817-1828
volume
396
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2021 Jul 3;398(10294):24. doi: 10.1016/S0140-6736(21)00380-9.
    note
    Source null
    related pmid
    34217392
    relationship
    Comment in
outcomes validated
false
pmid
33278935
provenance
batch id
9bca82d1bba2b27adc79
provider
NCBI PubMed ESummary
record sha256
4d038f3966cd737d7012204a36d3523ff9ebf6a9af8ca52afbb930d53fad2177
response sha256
c8a4853c65a45038af15f5ade3970763bfa121cf5c68bafcc52c3a06860d0211
retrieved at
2026-09-09T23:47:56.131551+00:00
publication date
display
2020 Dec 5
precision
day
year
2020
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/33278935/
title
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.

Preserved source evidence · Not medical advice